LIGAND PHARMACEUTICALS INC: Invesco Ltd. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Invesco Ltd. amended its Schedule 13G filing with the SEC (accession 0000914208-26-000430) covering its stake in Ligand Pharmaceuticals Inc. The filing updates Invesco's previously reported beneficial ownership position in the company. Schedule 13G amendments are required when a passive investor's holdings cross certain thresholds or change materially. The revised stake matters because it signals a shift in institutional ownership for Ligand, a drug developer that earns royalties on partnered medicines. Investors will watch for the specific share count and percentage disclosed in the amendment, and any further 13G or 13D activity from other large holders.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Ligand Pharmaceuticals Inc, Invesco Ltd.